H.C. Wainwright raised the firm’s price target on ALX Oncology to $25 from $20 and keeps a Buy rating on the shares post the Q1 report.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology Appoints Allison Dillon as Chief Business Officer
- ALX Oncology appoints Dillon as Chief Business Officer
- ALX Oncology Board Reshuffles Following Director Resignations
- ALX Oncology announces initiation of Phase 2 trial in patients with HPVOC
- ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting